Vcanbio Cell & Gene Engineering Corp., Ltd. Class A

Vcanbio Cell & Gene Engineering Corp., Ltd. Class A

SSSE:600645
16.20
CNY
-0.28
(-1.70%)
0.23EPS
79.88P/E
9.08BMarket Cap
Apr 23Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1
1.34
1.84
2.21
3.82
3.34
3.07
2.81
3.26
3.3
3.43
3.48
3.2
2.97
Basic EPS, GAAP
0.02
0.1
0.54
0.1
0.03
0.15
0.11
-0.27
0.33
0.24
0.23
0.22
0.25
0.24
Free Cash Flow per Basic Share
0.11
0.45
-0.31
-0.33
0.05
- -
0.26
0.32
0.41
0.35
0.45
0.48
0.58
- -
Dividend per Share
0.04
- -
0.03
0.02
0.03
0.03
0.03
0.01
- -
- -
- -
- -
- -
- -
Book Value per Share
1.44
2.93
4.02
4.11
7.14
6.29
7.17
7.3
7.4
7.6
7.87
7.68
7.92
8.16
Tangible Book Value per Share
1.2
1.1
2.26
2.26
3.44
3.47
4.72
5.43
5.58
5.8
6.06
5.84
6.08
6.35
Basic Weighted Avg Shares
361
355
386
379
346
395
452
470
471
471
463
456
455
463
Sales/Revenue/Turnover
361
477
709
838
1,321
1,321
1,387
1,319
1,535
1,555
1,590
1,585
1,455
1,375
Operating Margin (%)
1.25
10.97
15.4
14.15
8.22
8.38
14.41
9.29
12.46
10.92
11.32
12.84
13.51
14.03
Depreciation Expense
33
34
45
56
101
102
96
103
125
138
144
142
139
- -
Net Income, GAAP
7
35
208
38
10
59
50
-127
155
113
106
100
114
113
Effective Tax Rate (%)
24.87
25.75
17.24
46.17
60.02
37.01
52.45
- -
32.18
31.26
25.67
34.27
40.65
42.88
Profit Margin (%)
2
7.44
29.39
4.52
0.78
4.49
3.58
-9.62
10.12
7.27
6.7
6.33
7.82
8.18
Working Capital
99
-251
-167
-351
-47
117
556
591
635
839
1,027
969
1,199
1,321
LT Debt
- -
- -
38
79
141
119
35
79
48
102
86
68
47
44
Total Equity
660
1,156
1,682
1,752
2,965
2,981
3,461
3,521
3,533
3,654
3,799
3,659
3,755
3,854
Return on Invested Capital (%)
0.57
4.65
14.46
2.41
0.86
2.04
1.54
- -
4.2
2.97
2.6
2.41
2.91
- -
Return on Capital (%)
1.11
2.65
14.43
1.68
- -
1.88
1.49
- -
4.44
3.25
2.99
2.91
3.27
- -
Return on Common Equity (%)
2.23
4.62
16.11
2.41
0.48
2.14
1.62
-3.75
4.52
3.22
2.94
2.76
3.12
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
21
26
21
LT Borrowings
- -
- -
- -
LT Finance Leases
53
42
44
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
468
468
468
Market Capitalization
14,460
8,007
9,083

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,662
2,725
2,740
Cash, Cash Equivalents & STI
1,735
1,818
1,829
Accounts Receivable, Net
582
563
576
Inventories
232
236
239
Total Current Liabilities
1,413
1,430
1,418
Payables & Accruals
- -
- -
- -
ST Debt
21
26
21
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.85%
1.33%
2.62%
Free Cash Flow
588.1%
12.98%
21.21%
Net Income, GAAP
-30.21%
-49.55%
13.43%
Sales/Revenue/Turnover
8.73%
2.28%
-8.23%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
398
404
404
380
1,585
2025
351
366
- -
362
1,455
2026
317
342
354
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.09
0.1
0.11
-0.07
0.22
2025
0.06
0.07
- -
0.01
0.25
2026
0.05
0.08
0.1
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Hong Qi Wang
Full Time Employees
1,935
Sector
Commercial services
Industry
Miscellaneous commercial services
Address
Huayuan Industrial Park Tianjin TI China 300384
IPO Date
May 4, 1993
Business
I could not find direct search results specific to the latest major company changes for Vcanbio Cell & Gene Engineering Corp., Ltd (Ticker: 600645.SS). I will conduct a direct website fetch from the official company site to obtain comprehensive and accurate current information on their products, services, and recent major changes. Fetching from https://www.vcanbio.com now.